This Cellular Immunotherapy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $5.72 billion in 2024 to $6.61 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to cancer treatment advancements, clinical success stories, regulatory approvals, growing incidence of targeted diseases.
The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $11.27 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to expansion to solid tumors, improved manufacturing, healthcare infrastructure, research funding. Major trends in the forecast period include research and development investments, clinical trial data, combination therapies.
The growth of the cellular immunotherapy market is being propelled by increasing research and successful clinical trials in the field. Companies are dedicated to developing new cellular immunotherapies to address various diseases. As of April 2022, there were 2,756 active cell therapy drugs globally, a 36% increase from 2021, indicating rapid growth in this sector. This growth, particularly in clinical and preclinical stages, is expected to expand the cellular immunotherapy landscape, driving market revenues higher.
The prevalence of cancer is another factor expected to drive the growth of the cellular immunotherapy market. Cancer is a group of diseases characterized by uncontrolled cell growth, spurring research and investment in cancer therapies, including cellular immunotherapies. These therapies leverage the patient's immune system to combat cancer cells, contributing to the rise of cellular immunotherapies. For instance, the estimated number of people living with cancer in the UK is projected to rise from the current 3 million to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This growing prevalence highlights the increasing demand for improved cancer care, treatment options, and supportive services, driving advancements and growth in the healthcare and pharmaceutical markets. This underscores the growing demand for effective cancer treatments, further boosting the cellular immunotherapy market.
Companies in the cellular immunotherapy market are focusing on the development of off-the-shelf allogeneic therapies to improve cancer treatment. These therapies use donor cells rather than the patient's cells, offering benefits such as cost-effectiveness, large-scale production, speed, and quality control. Novartis, for example, received expedited FDA approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma. Acepodia initiated a phase 1 clinical trial for ACE1702, an allogeneic, off-the-shelf NK cell therapy to treat solid tumors.
Major companies in the cellular immunotherapy market are focusing on technological advancements, such as innovative immunotherapies, to enhance treatment efficacy and broaden their applications. This includes developments in personalized medicine, combination therapies, and scalable manufacturing processes to improve patient outcomes. Immunotherapy is a treatment that leverages the body’s immune system to combat diseases like cancer, either by boosting immune responses or employing targeted therapies to focus immune activity on specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, introduced CAR-T cell therapy. This groundbreaking cancer treatment employs genetically engineered T cells designed to target and destroy cancer cells, providing a highly personalized approach. CAR-T cell therapy has shown remarkable effectiveness in achieving durable remission rates, particularly in treatment-resistant blood cancers, while minimizing harm to healthy tissues.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. This strategic acquisition aims to bolster AstraZeneca's oncology portfolio by advancing the development of innovative T-cell receptor therapies for solid tumors. Neogene Therapeutics, a US-based biotechnology company, specializes in personalized cellular immunotherapy by engineering T-cells to target specific cancer cells, offering a promising approach to treating various types of cancer.
Cellular immunotherapy represents an innovative approach to immunotherapy where patients are administered T cells, a type of immune cell, to assist the body in combating diseases such as cancer. It harnesses the body's immune system to fight against cancer.
The key therapies within cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy involving the extraction of lymphocytes that have infiltrated tumors, their cultivation and amplification in vitro, and subsequent infusion into patients for therapeutic purposes. This therapy finds application in various primary indications, including b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and is utilized in the treatment of conditions such as prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and more.
The cellular immunotherapy market research report is one of a series of new reports that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd., Green Cross Corp, AstraZeneca PLC, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics PLC, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation.
North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $5.72 billion in 2024 to $6.61 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to cancer treatment advancements, clinical success stories, regulatory approvals, growing incidence of targeted diseases.
The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $11.27 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to expansion to solid tumors, improved manufacturing, healthcare infrastructure, research funding. Major trends in the forecast period include research and development investments, clinical trial data, combination therapies.
The growth of the cellular immunotherapy market is being propelled by increasing research and successful clinical trials in the field. Companies are dedicated to developing new cellular immunotherapies to address various diseases. As of April 2022, there were 2,756 active cell therapy drugs globally, a 36% increase from 2021, indicating rapid growth in this sector. This growth, particularly in clinical and preclinical stages, is expected to expand the cellular immunotherapy landscape, driving market revenues higher.
The prevalence of cancer is another factor expected to drive the growth of the cellular immunotherapy market. Cancer is a group of diseases characterized by uncontrolled cell growth, spurring research and investment in cancer therapies, including cellular immunotherapies. These therapies leverage the patient's immune system to combat cancer cells, contributing to the rise of cellular immunotherapies. For instance, the estimated number of people living with cancer in the UK is projected to rise from the current 3 million to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This growing prevalence highlights the increasing demand for improved cancer care, treatment options, and supportive services, driving advancements and growth in the healthcare and pharmaceutical markets. This underscores the growing demand for effective cancer treatments, further boosting the cellular immunotherapy market.
Companies in the cellular immunotherapy market are focusing on the development of off-the-shelf allogeneic therapies to improve cancer treatment. These therapies use donor cells rather than the patient's cells, offering benefits such as cost-effectiveness, large-scale production, speed, and quality control. Novartis, for example, received expedited FDA approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma. Acepodia initiated a phase 1 clinical trial for ACE1702, an allogeneic, off-the-shelf NK cell therapy to treat solid tumors.
Major companies in the cellular immunotherapy market are focusing on technological advancements, such as innovative immunotherapies, to enhance treatment efficacy and broaden their applications. This includes developments in personalized medicine, combination therapies, and scalable manufacturing processes to improve patient outcomes. Immunotherapy is a treatment that leverages the body’s immune system to combat diseases like cancer, either by boosting immune responses or employing targeted therapies to focus immune activity on specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, introduced CAR-T cell therapy. This groundbreaking cancer treatment employs genetically engineered T cells designed to target and destroy cancer cells, providing a highly personalized approach. CAR-T cell therapy has shown remarkable effectiveness in achieving durable remission rates, particularly in treatment-resistant blood cancers, while minimizing harm to healthy tissues.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. This strategic acquisition aims to bolster AstraZeneca's oncology portfolio by advancing the development of innovative T-cell receptor therapies for solid tumors. Neogene Therapeutics, a US-based biotechnology company, specializes in personalized cellular immunotherapy by engineering T-cells to target specific cancer cells, offering a promising approach to treating various types of cancer.
Cellular immunotherapy represents an innovative approach to immunotherapy where patients are administered T cells, a type of immune cell, to assist the body in combating diseases such as cancer. It harnesses the body's immune system to fight against cancer.
The key therapies within cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy involving the extraction of lymphocytes that have infiltrated tumors, their cultivation and amplification in vitro, and subsequent infusion into patients for therapeutic purposes. This therapy finds application in various primary indications, including b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and is utilized in the treatment of conditions such as prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and more.
The cellular immunotherapy market research report is one of a series of new reports that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd., Green Cross Corp, AstraZeneca PLC, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics PLC, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation.
North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cellular Immunotherapy Market Characteristics3. Cellular Immunotherapy Market Trends and Strategies4. Cellular Immunotherapy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Cellular Immunotherapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cellular Immunotherapy Market34. Recent Developments in the Cellular Immunotherapy Market
5. Global Cellular Immunotherapy Growth Analysis and Strategic Analysis Framework
6. Cellular Immunotherapy Market Segmentation
7. Cellular Immunotherapy Market Regional and Country Analysis
8. Asia-Pacific Cellular Immunotherapy Market
9. China Cellular Immunotherapy Market
10. India Cellular Immunotherapy Market
11. Japan Cellular Immunotherapy Market
12. Australia Cellular Immunotherapy Market
13. Indonesia Cellular Immunotherapy Market
14. South Korea Cellular Immunotherapy Market
15. Western Europe Cellular Immunotherapy Market
16. UK Cellular Immunotherapy Market
17. Germany Cellular Immunotherapy Market
18. France Cellular Immunotherapy Market
19. Italy Cellular Immunotherapy Market
20. Spain Cellular Immunotherapy Market
21. Eastern Europe Cellular Immunotherapy Market
22. Russia Cellular Immunotherapy Market
23. North America Cellular Immunotherapy Market
24. USA Cellular Immunotherapy Market
25. Canada Cellular Immunotherapy Market
26. South America Cellular Immunotherapy Market
27. Brazil Cellular Immunotherapy Market
28. Middle East Cellular Immunotherapy Market
29. Africa Cellular Immunotherapy Market
30. Cellular Immunotherapy Market Competitive Landscape and Company Profiles
31. Cellular Immunotherapy Market Other Major and Innovative Companies
35. Cellular Immunotherapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cellular Immunotherapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cellular immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cellular immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cellular immunotherapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy; Engineered T Cell Receptor (TCR) Therapy; Chimeric Antigen Receptor (CAR) T Cell Therapy; Natural Killer (NK) Cell Therapy2) By Primary Indication: B-cell Malignancies; Prostate Cancer; Renal Cell Carcinoma; Liver Cancer; Non-Hodgkin lymphoma; Other Primary Indications
3) By Application: Prostate Cancer; Breast Cancer; Skin Cancer; Ovarian Cancer; Brain Tumor; Lung Cancer; Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy; Allogeneic TIL Therapy; Other TIL Therapy2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy; Gamma-Delta TCR Therapy; Other Engineered TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy; Allogeneic CAR T Cell Therapy; CAR T Cell Therapy for Solid Tumors; CAR T Cell Therapy for Hematologic Malignancies; Other CAR T Cell Therapy
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy; Allogeneic NK Cell Therapy; NK Cell Therapy With Engineered Modifications; Other NK Cell Therapy
Key Companies Mentioned: Novartis International AG; Gilead Sciences Inc.; Apac Biotech; Dendreon Pharmaceuticals LLC; JW CreaGene Co. Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Cellular Immunotherapy market report include:- Novartis International AG
- Gilead Sciences Inc.
- Apac Biotech
- Dendreon Pharmaceuticals LLC
- JW CreaGene Co. Ltd
- Green Cross Corp
- AstraZeneca plc
- Bristol Myers Squibb Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Adicet Bio Inc.
- ResTORbio Inc.
- Celyad SA
- Merck KGaA
- GlaxoSmithKline plc.
- Johnson & Johnson
- Adaptimmune Therapeutics plc
- AVROBIO Inc.
- Cellular Biomedicine Group Inc.
- Kite Pharma Inc.
- Juno Therapeutics Inc.
- Celgene Corporation
- Bluebird Bio Inc.
- Tmunity Therapeutics Inc.
- Atara Biotherapeutics Inc.
- Fate Therapeutics Inc.
- Precision Biosciences Inc.
- Allogene Therapeutics Inc.
- CRISPR Therapeutics AG
- Sangamo Therapeutics Inc.
- Intellia Therapeutics Inc.
- Editas Medicine Inc.
- Caribou Biosciences Inc.
- Mammoth Biosciences Inc.
- Synthego Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 6.61 Billion |
| Forecasted Market Value ( USD | $ 11.27 Billion |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 36 |
